Dr. Choueiri on the Role of Cabozantinib in RCC

Video

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma (RCC).

There is potential for cabozantinib to be an option in the frontline setting for patients with RCC, states Choueiri.In the results of the phase II CABOSUN trial, cabozantinib showed superiority in progression-free survival (PFS).

It could become an option for patients with intermediate and poor-risk RCC that are completely untreated and systemic therapy naïve, explains Choueiri.

Related Videos
John Shen, MD
Tatyana Feldman, MD
A panel of 4 experts on bladder cancer
Matthew Milowsky, MD, FASCO, an expert on bladder cancer
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD